CS
PVLA

Credit Suisse’s Palvella Therapeutics PVLA Stock Holding History

Credit Suisse’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-862
Closed -$356K – 4697
2021
Q3 		$356K Sell
862
-97
-10% -$33.8K ﹤0.01% 4016
2021
Q2 		$294K Sell
959
-59
-6% -$12.9K ﹤0.01% 4121
2021
Q1 		$209K Sell
1,018
-119
-10% -$26K ﹤0.01% 4110
2020
Q4 		$227K Buy
1,137
+150
+15% +$31.2K ﹤0.01% 4061
2020
Q3 		$163K Sell
987
-34
-3% -$7.74K ﹤0.01% 3871
2020
Q2 		$253K Buy
1,021
+62
+6% +$14.5K ﹤0.01% 3662
2020
Q1 		$175K Buy
+959
New +$242K ﹤0.01% 3693
2019
Q4 		– Sell
-237
Closed -$64K – 4365
2019
Q3 		$64K Buy
+237
New +$91.8K ﹤0.01% 4014
2019
Q2 		– Sell
-159
Closed -$42K – 4260
2019
Q1 		$42K Buy
+159
New +$37.8K ﹤0.01% 3913
2018
Q3 		– Sell
-171
Closed -$69K – 4033
2018
Q2 		$69K Sell
171
-24
-12% -$11.4K ﹤0.01% 3872
2018
Q1 		$106K Buy
195
+68
+54% +$42.1K ﹤0.01% 3792
2017
Q4 		$77K Sell
127
-162
-56% -$75.3K ﹤0.01% 3872
2017
Q3 		$133K Buy
289
+158
+121% +$67.5K ﹤0.01% 4034
2017
Q2 		$54K Buy
+131
New +$38.3K ﹤0.01% 3776

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse's PVLA Position: Q4 2021 in Review

Credit Suisse sold out of Palvella Therapeutics (PVLA) in Q4 2021, closing a stake of 862 shares — an estimated $356K sold.

Credit Suisse first reported a position in PVLA in Q2 2017 and held it in 14 quarters. The position peaked at $356K in Q3 2021. 81 funds tracked by Wall St. Rank hold PVLA as of Q4 2021.

  • Credit Suisse reported no remaining Palvella Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Credit Suisse sold 862 Palvella Therapeutics shares in Q4 2021, an estimated $356K.
  • Credit Suisse first reported a position in Palvella Therapeutics in Q2 2017 and held it in 14 quarters.
  • Credit Suisse's Palvella Therapeutics position peaked at $356K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2021.

Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.